Here are three updates on GI companies from the past week:
Boehringer Ingelheim Pharmaceuticals's Cyltezo, a second biosimilar for AbbVie's Humira, received FDA approval.
AzurRx BioPharma enrolled a sixth patient into its phase IIa trial for MS1819, a treatment for exocrine pancreatic insufficiency associated with chronic pancreatitis.
4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial.